ArticleCell reports. Medicine2021
A comprehensive analysis and resource to use CRISPR-Cas13 for broad-spectrum targeting of RNA viruses.
Article in Cell reports. Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Development of a CRISPR-Cas13-based antiviral strategy against hepatitis E virus.JHEP reports : innovation in hepatology · 2026Article
- Broad-spectrum CRISPR-Cas13d-mediated strategy for combating human coronaviruses.Molecular therapy. Nucleic acids · 2026Article
- CRISPR Treatments for AI-Designed Synthetic Viruses: Rapid Programmable Countermeasures for Emerging and Engineered Viruses.Viruses · 2025Review
- CRISPR/Cas genome editing, functional genomics, and diagnostics for parasitic helminths.International journal for parasitology · 2025Review
- Cross-species tropism of AAV.CPP.16 in the respiratory tract and its gene therapies against pulmonary fibrosis and viral infection.Cell reports. Medicine · 2025Article
- Fighting RNA viruses with a gold nanoparticle Cas13d gene-editing armor.Molecular therapy. Nucleic acids · 2025Article
- A Susceptible Cell-Selective Delivery (SCSD) of mRNA-Encoded Cas13d Against Influenza Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Targeting pseudoknots with Cas13b inhibits porcine epidemic diarrhoea virus replication.The Journal of general virology · 2025Article
- Review
- Article
- CRISPR-dCas13a system for programmable small RNAs and polycistronic mRNA repression in bacteria.Nucleic acids research · 2024Article
- Pan-Coronavirus CRISPR-CasRx Effector System Significantly Reduces Viable Titer in HCoV-OC43, HCoV-229E, and SARS-CoV-2.The CRISPR journal · 2023Article
- Pseudoknot-targeting Cas13b combats SARS-CoV-2 infection by suppressing viral replication.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Functional nucleic acids as potent therapeutics against SARS-CoV-2 infection.Cell reports. Physical science · 2023Review
- Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment.Genes & diseases · 2022Review
- Polyvalent guide RNAs for CRISPR antivirals.iScience · 2022Article
- Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine.International immunopharmacology · 2022Review
- Transcriptomics and RNA-Based Therapeutics as Potential Approaches to Manage SARS-CoV-2 Infection.International journal of molecular sciences · 2022Review
- Designing sensitive viral diagnostics with machine learning.Nature biotechnology · 2022Article
- Advancements in Testing Strategies for COVID-19.Biosensors · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and variants has led to significant mortality. We recently reported that an RNA-targeting CRISPR-Cas13 system, called prophylactic antiviral CRISPR in human cells (PAC-MAN), offered an antiviral strategy against SARS-CoV-2 and influenza A virus. Here, we expand
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.